新型冠状病毒感染者抗病毒治疗专家共识  

Expert consensus on antiviral therapy of COVID-19

作　　者：张福杰[1] 王卓 王全红[3] 毛青 白劲松 叶寒辉 田佳[7] 向天新[8] 安纪红 余祖江[10] 杨文杰[11] 杨兴祥[12] 张晓菊[13] 张捷[14] 张丽娜[15] 李兴旺[1] 李家斌[16] 李满祥[17] 李智伟[18] 周厚荣[19] 施毅 徐晓玲[21] 唐小平[22] 唐红[23] 阎锡新[24] 黄文祥[25] 黄朝林 董亮 谢宝松[28] 蒋建东 熊滨[30] 魏雪梅[31] 盛吉芳[32] 金荣华 Zhang Fujie;Wang Zhuo;Wang Quanhong;Mao Qing;Bai Jinsong;Ye Hanhui;Tian Jia;Xiang Tianxin;An Jihong;Yu Zujiang;Yang Wenjie;Yang Xingxiang;Zhang Xiaoju;Zhang Jie;Zhang Lina;Li Xingwang;Li Jiabin;Li Manxiang;Li Zhiwei;Zhou Hourong;Shi Yi;Xu Xiaoling;Tang Xiaoping;Tang Hong;Yan Xixin;Huang Wenxiang;Huang Chaolin;Dong Liang;Xie Baosong;Jiang Jiandong;Xiong Bin;Wei Xuemei;Sheng Jifang;Jin Ronghua(Department of Infectious Diseases,Beijing Ditan Hospital Capital Medical University,Beijing 100015,China;Department of Pharmacy,Changhai Hospital of Shanghai,Shanghai 200433,China;Department of Tuberculosis Internal Medicine,the Fourth People’s Hospital of Taiyuan,Taiyuan 030000,Shanxi Province,China;Department of Infectious Diseases,the Southwest Hospital of AMU,Chongqing 400000,China;Department of Infectious Diseases,Kunming Third People’s Hospital,Kunming 650000,Yunnan Province,China;Department of Infectious Diseases,Mengchao Hepatobiliary Hospital of Fujian Medical University,Fuzhou 350000,Fujian Province,China;Department of Critical Care Medicine,Hainan Provincial People’s Hospital,Haikou 570100,Hainan Province,China;Department of Infectious Diseases,the First Affiliated Hospital of Nanchang University,Nanchang 330000,Jiangxi Province,China;Department of Infectious Diseases,Inner Mongolia Autonomous Region People’s Hospital,Hohhot 010010,Inner Mongolia Autonomous Region,China;Department of Infectious Diseases,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China;Department of Infectious Diseases,Tianjin Frst Central Hospital,Tianjin 300000,China;Department of Infectious Diseases,Sichuan Provincial People’s Hospital,Chengdu 610000,Sichuan Province,China;Department of Respiratory and Critical Care,Henan Provincial People’s Hospital,Zhengzhou 450000,Henan Province,China;Department of Respiratory and Critical Care,the Second Hospital of Jilin University,Changchun 132000,Jilin Province,China;Department of Critical Care Medicine,Xiangya Hospital Central South University,Changsh

机构地区：[1]首都医科大学附属北京地坛医院感染科,100015 [2]上海长海医院药剂科,200433 [3]山西医科大学附属肺科医院结核内科,太原030000 [4]陆军军医大学第一附属医院感染科,重庆400000 [5]昆明市第三人民医院感染科,650000 [6]福建医科大学孟超肝胆医院感染科,福州350000 [7]海南省人民医院重症医学科,海口570100 [8]南昌大学第一附属医院感染科,330000 [9]内蒙古自治区人民医院感染科,呼和浩特010010 [10]郑州大学第一附属医院感染科,450000 [11]天津市第一中心医院感染科,300000 [12]四川省人民医院感染科,成都610000 [13]河南省人民医院呼吸与危重症医学科,郑州450000 [14]吉林大学第二医院呼吸与危重症医学科,长春132000 [15]中南大学湘雅医院重症医学科,长沙410000 [16]安徽医科大学第一附属医院感染科,合肥230022 [17]西安交通大学第一附属医院呼吸与危重症医学科,710000 [18]中国医科大学附属盛京医院感染科,沈阳110000 [19]贵州省人民医院全科医学科,贵阳550000 [20]南京大学医学院附属金陵医院呼吸与危重症医学科,210000 [21]中国科学技术大学附属第一医院呼吸与危重症医学科,合肥230000 [22]广州医科大学感染科,510000 [23]四川大学华西医院感染科,成都610000 [24]河北医科大学第二医院呼吸与危重症医学科,石家庄050000 [25]重庆医科大学附属第一医院老年病科,400000 [26]武汉市金银潭医院感染科,430000 [27]山东第一医科大学第一附属医院呼吸内科,济南250000 [28]福建省立医院呼吸内科,福州350000 [29]中国医学科学院药物研究院,北京100000 [30]广西壮族自治区人民医院重症医学科,南宁530000 [31]新疆维吾尔自治区人民医院呼吸与危重医学症科,乌鲁木齐830000 [32]浙江大学医学院附属第一医院感染科,杭州310003

出　　处：《中华临床感染病杂志》2023年第1期10-20,共11页Chinese Journal of Clinical Infectious Diseases

基　　金：国家重点研发计划(2021YFC0864600、2020YFC0861200)。

摘　　要：新型冠状病毒感染(COVID-19)由一种名为严重急性呼吸系统综合征冠状病毒2(SARS-CoV-2,简称新冠病毒)引起,至今仍在全球范围内不断蔓延,对人类健康和生命造成了严重威胁。中和抗体和针对病毒复制周期的小分子抑制剂是我国目前推荐的针对新冠病毒的主要抗病毒治疗方案。为进一步促进抗新冠病毒药物在临床合理应用,国家传染病医学中心(首都医科大学附属北京地坛医院和浙江大学医学院附属第一医院)组织国内感染、呼吸、重症、药学专家对相关资料进行整理和分析,在《新型冠状病毒感染诊疗方案(试行第十版)》基础上结合我国针对COVID-19的诊疗经验,编写了简单实用、可操作性强的《新型冠状病毒感染者抗病毒治疗专家共识》,以期提高临床医师对抗新冠病毒药物的认识,为临床医师规范用药提供建议。COVID-19 is caused by a novel coronavirus-severe acute respiratory syndrome coronavirus type 2(SARS-CoV-2),which has being spreading around the world,posing a serious threat to human health and lives.Neutralizing antibodies and small molecule inhibitors for virus replication cycle are the main antiviral treatment for novel coronavirus recommended in China.To further promote the rational use of antiviral therapy in clinical practice,the National Center for Infectious Diseases(Beijing Ditan Hospital Capital Medical University and the First Affiliated Hospital,Zhejiang University School of Medicine)invited experts in fields of infectious diseases,respiratory and intensive care to develop an Expert Consensus on Antiviral Therapy of COVID-19 based on the Diagnosis and Treatment Guideline for COVID-19(trial version 10)and experiences in the diagnosis and treatment of COVID-19 in China.The consensus is concise,practical and highly operable,hopefully it would improve the understanding of antiviral therapy for clinicians and provide suggestions for standardized medication in treatment of COVID-19.

关 键 词：冠状病毒 新型冠状病毒感染 抗病毒治疗 早期 专家共识 

分 类 号：R511[医药卫生—内科学]